Company attributes
B2X
CEO
Founder
Pitchbook URL
Legal Name
Aurinia Pharmaceuticals Inc.
Number of Employees (Ranges)
201 – 500
Email Address
bd@auriniapharma.com0
medinfo@auriniapharma.com0
aurinia@westwicke.com0
clinicaltrials@auriniapharma.com0
Phone Number
+125074424870
Full Address
201-17873 – 106 A Avenue Edmonton, AB T5S 1V8 Canada0
1203-4464 Markham Street Victoria, BC V8Z 7X8 Canada0
77 Upper Rock Circle – Suite 700 Rockville, MD 20850 USA0
CIK Number
Place of Incorporation
Investors
Founded Date
1993
Fax Number
+1 (250) 708-43450
Total Funding Amount (USD)
451,550,000
Latest Funding Round Date
December 12, 2019
Competitors
Stock Symbol
AUPH0
AUP
Exchange
Board of Directors
CFO
NAICS Code
325,4120
Patents Assigned (Count)
7
Country
Other attributes
Company Operating Status
Active
Contact Page URL
SIC Code
2,8340
Ticker Symbol
AUPH
Aurinia Pharmaceuticals is a clinical biopharmaceutical company that focuses on developing and commercializing therapies for treating targeted patient populations that are seriously affected by diseases with challenging medical need. Aurinia is exploring the potential of novel therapies to address patients' needs. Approved therapies include that for lupus nephritis, and they are in the process of pursuing a wider portfolio of innovative drugs for autoimmune disease.
Timeline
No Timeline data yet.
Funding Rounds
Products
Acquisitions
SBIR/STTR Awards
Patents
Further Resources
No Further Resources data yet.
